ECTRIMS 2024 Late Breaking Poster

IF 4.8 2区医学 Q1 CLINICAL NEUROLOGY Multiple Sclerosis Journal Pub Date : 2024-09-17 DOI:10.1177/13524585241269220

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

ECTRIMS 2024 最新海报

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Multiple Sclerosis Journal 医学-临床神经学

CiteScore

10.90

自引率

6.90%

发文量

186

审稿时长

3-8 weeks

期刊介绍： Multiple Sclerosis Journal is a peer-reviewed international journal that focuses on all aspects of multiple sclerosis, neuromyelitis optica and other related autoimmune diseases of the central nervous system. The journal for your research in the following areas: * __Biologic basis:__ pathology, myelin biology, pathophysiology of the blood/brain barrier, axo-glial pathobiology, remyelination, virology and microbiome, immunology, proteomics * __Epidemology and genetics:__ genetics epigenetics, epidemiology * __Clinical and Neuroimaging:__ clinical neurology, biomarkers, neuroimaging and clinical outcome measures * __Therapeutics and rehabilitation:__ therapeutics, rehabilitation, psychology, neuroplasticity, neuroprotection, and systematic management Print ISSN: 1352-4585

期刊最新文献

Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: A call for standardization and transparency in clinical practice. Homonymous hemi-macular atrophy in multiple sclerosis. Cryptogenic organising pneumonia in patients treated with ocrelizumab. Ocrelizumab-associated cryptogenic organizing pneumonia in multiple sclerosis: Two case reports and comprehensive literature review. Vaccination as a risk factor for pediatric multiple sclerosis: Insights from a retrospective case-control study.